Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 Dose Optimization in Relapsed/Refractory CLL
NCT01747486Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Jan 2013
- Primary completion
- Dec 2017
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CD19 CAR-T cells in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Pennsylvania. Started Jan 2013; status: completed.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01747486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01747486.